Discovery of metal ions chelator quercetin derivatives with potent anti-HCV activities

Molecules

Volumn 20, Issue 4, 2015, Pages 6978-6999

  Zhong, Dongwei ^a   Liu, Mingming ^a   Cao, Yang ^a   Zhu, Yelin ^a   Bian, Shihui ^a   Zhou, Jiayi ^a   Wu, Fengjie ^a   Ryu, Kum Chol ^b   Zhou, Lu ^a   Ye, Deyong ^a  

^a FUDAN UNIVERSITY   (China)

^b Ham Hung Pharmaceutical University   (South Korea)

Author keywords

Anti HCV activities; Diketoacids mimic; Docking; Quercetin derivatives; Synthesis

Indexed keywords

ANTIVIRUS AGENT; CHELATING AGENT; MAGNESIUM; NS-5 PROTEIN, HEPATITIS C VIRUS; QUERCETIN; VIRUS PROTEIN;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME ACTIVE SITE; HEPACIVIRUS; HUMAN; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CHELATING AGENTS; DRUG DISCOVERY; HEPACIVIRUS; HUMANS; MAGNESIUM; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; QUERCETIN; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84928737087     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20046978     Document Type: Article

References (25)

1. Mohd Hanafiah, K.; Groeger, J.; Flaxman, A.D.; Wiersma, S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57, 1333-1342.
2. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Gonçales, F.L., Jr.; Häussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-982.
3. Feld, J.J.; Hoofnagle, J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436, 967-972.
4. Kwong, A.D.; Kauffman, R.S.; Hurter, P.; Mueller, P. Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 2011, 29, 993-1003.
5. Berman, K.; Kwo, P.Y. Boceprevir, an NS3 protease inhibitor of HCV. Clin. Liver Dis. 2009, 13, 429-439.
6. Rosenquist, Å.; Samuelsson, B.; Johansson, P.-O.; Cummings, M.D.; Lenz, O.; Raboisson, P.; Simmen, K.; Vendeville, S.; de Kock, H.; Nilsson, M. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem. 2014, 57, 1673-1693.
7. Asselah, T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin. Pharmacother. 2014, 15, 121-130.
8. Hiraga, N.; Imamura, M.; Abe, H.; Hayes, C.N.; Kono, T.; Onishi, M.; Tsuge, M.; Takahashi, S.; Ochi, H.; Iwao, E. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011, 54, 781-788.
9. Steinbrook, R.; Redberg, R.F. The High Price of the New Hepatitis C Virus Drugs. JAMA Intern. Med. 2014, 174, 1172-1172.
10. Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R.L.; Mathieu, M.; de Francesco, R.; Rey, F.A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA 1999, 96, 13034-13039.
11. Summa, V.; Petrocchi, A.; Pace, P.; Matassa, V.G.; de Francesco, R.; Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. Discovery of α, γ-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem. 2004, 47, 14-17.
12. Summa, V.; Petrocchi, A.; Matassa, V.G.; Taliani, M.; Laufer, R.; de Francesco, R.; Altamura, S.; Pace, P. HCV NS5b RNA-dependent RNA polymerase inhibitors: From α, γ-diketoacids to 4, 5-dihydroxypyrimidine-or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis. J. Med. Chem. 2004, 47, 5336-5339.
13. Summa, V.; Petrocchi, A.; Matassa, V.G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Paz, O.G.; Laufer, R.; Monteagudo, E.; Pace, P. 4, 5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J. Med. Chem. 2006, 49, 6646-6649.
14. Pace, P.; Nizi, E.; Pacini, B.; Pesci, S.; Matassa, V.; de Francesco, R.; Altamura, S.; Summa, V. The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett. 2004, 14, 3257-3261.
15. Maalik, A.; Khan, F.A.; Mumtaz, A.; Mehmood, A.; Azhar, S.; Atif, M.; Karim, S.; Altaf, Y.; Tariq, I. Pharmacological Applications of Quercetin and its Derivatives: A Short Review. Trop. J. Pharm. Res. 2014, 13, 1561-1566.
16. Liu, M.-M.; Zhou, L.; He, P.-L.; Zhang, Y.-N.; Zhou, J.-Y.; Shen, Q.; Chen, X.-W.; Zuo, J.-P.; Li, W.; Ye, D.-Y. Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy. Eur. J. Med. Chem. 2012, 52, 33-43.
17. Ahmed-Belkacem, A.; Guichou, J.-F.; Brillet, R.; Ahnou, N.; Hernandez, E.; Pallier, C.; Pawlotsky, J.-M. Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: A new mechanism for antiviral intervention. Nucleic Acids Res. 2014, 42, 9399-9409.
18. Lee, C.; Lee, J.M.; Lee, N.-R.; Kim, D.-E.; Jeong, Y.-J.; Chong, Y. Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives. Bioorg. Med. Chem. Lett. 2009, 19, 4538-4541.
19. Huang, H.; Jia, Q.; Ma, J.; Qin, G.; Chen, Y.; Xi, Y.; Lin, L.; Zhu, W.; Ding, J.; Jiang, H. Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors. Eur. J. Med. Chem. 2009, 44, 1982-1988.
20. Shi, Z.-H.; Li, N.-G.; Tang, Y.-P.; Yang, J.-P.; Duan, J.-A. Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors. Eur. J. Med. Chem. 2012, 54, 210-222.
21. Henry, S.D.; Metselaar, H.J.; Lonsdale, R.C.; Kok, A.; Haagmans, B.L.; van der Laan, L.J.; Tilanus, H.W. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-α. Gastroenterology 2006, 131, 1452-1462.
22. Bressanelli, S.; Tomei, L.; Rey, F.A.; de Francesco, R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 2002, 76, 3482-3492.
23. Yu, Y.; Jing, J.-F.; Tong, X.-K.; He, P.-L.; Li, Y.-C.; Hu, Y.-H.; Tang, W.; Zuo, J.-P. Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. Acta Pharmacol. Sinica 2014, 35, 1074-1081.
24. Han, Q.; Xu, C.; Wu, C.; Zhu, W.; Yang, R.; Chen, X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res. 2009, 145, 63-73.
25. Schrodinger, L. Schrodinger Software Suite; Schrödinger, LLC: New York, NY, USA, 2011.